{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '5.', 'STUDY OBJECTIVES AND ENDPOINTS', 'Disease response will be assessed according to the International Myeloma Working Group', '(IMWG) response criteria (based on Kumar 2016, Table 17).', '5.1.', 'Objectives', '5.1.1.', 'Primary Objective', \"To compare PFS based on the IRC's disease outcome assessments in patients\", 'randomized to the SVd Arm versus the Vd Arm', '5.1.2.', 'Secondary Objectives', \"To compare the ORR (> PR) based on the IRC's response outcome assessments\", '(Section 6.4), in patients randomized to the SVd Arm versus the Vd Arm', 'To compare the incidence of any Grade >2 peripheral neuropathy in patients', 'randomized to the SVd Arm versus patients randomized to the Vd Arm', 'To compare the number of patients with response > VGPR, > CR, > sCR, or minimal', 'residual disease (MRD) negative (for patients who achieve CR or sCR) in patients', 'randomized to the SVd Arm versus the Vd Arm', 'To compare OS in all patients randomized to the SVd Arm versus the Vd Arm', 'To compare the DOR in patients randomized to the SVd Arm versus the Vd Arm', 'To determine ORR1 (ORR during SVdX treatment only)', 'To determine PFS1 (PFS during SVdX treatment only)', 'To compare time-to-next-treatmen (TTNT) in patients randomized to the SVd Arm', 'versus the Vd Arm who receive post-SVd/Vd/SVdX/SdX treatment', 'To compare time-to-response (TTR) in patients randomized to the SVd Arm versus', 'the Vd Arm', 'To compare PFS2 (PFS on first post-SVd/Vd/SVdX treatment) in patients', 'randomized to the SVd Arm versus the Vd Arm who receive post-SVd/Vd/SVdX', 'treatment', 'To assess the safety and tolerability of treatment with SVd versus Vd in patients with', 'RRMM', 'To compare patient-reported peripheral neuropathy as measured by the European', 'Organization for Research and Treatment of Cancer (EORTC)', 'Chemotherapy-induced Peripheral Neuropathy (QLQ-CIPN20) instrument in patients', 'randomized to the SVd Arm versus the Vd Arm', '5.1.3.', 'Exploratory Objectives', 'Confidential', 'Page 44', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '5.1.4.', 'Pharmacokinetic Objective', 'To assess PK of bortezomib and selinexor in a subset of patients randomized to each', 'arm (ie, the SVd Arm versus the Vd Arm). The effect of co-administration of', 'bortezomib with selinexor on bortezomib or selinexor plasma levels will be', 'evaluated.', '5.2.', 'Endpoints', '5.2.1.', 'Primary Endpoint', 'PFS, defined as time from date of randomization until the first date of PD, per IMWG', 'response criteria, or death due to any cause, whichever occurs first. For the purposes', 'of PFS determination, PD will be determined by the IRC.', '5.2.2.', 'Secondary Efficacy Enppoints', '5.2.2.1.', 'Key Secondary Efficacy Enppoints', \"ORR, defined as any response >PR (ie, PR, VGPR, CR, or sCR) based on the IRC's\", 'response outcome assessments, according to the IMWG response criteria. All changes', 'in MM disease assessments will be based on baseline MM disease assessments.', 'Response rates at any time prior to PD or death due to any cause, pooled and', 'separately for the following responses: >VGPR, >CR, >sCR, or MRD negative (for', 'patients who achieve CR or sCR)', '5.2.2.2.', 'Non-Key Secondary Efficacy Endpoints', 'OS, defined as time to death or lost to follow-up, measured from the date of', 'randomization until death due to any cause or until lost to follow-up, for all patients', 'DOR, defined as the duration of time from first occurrence of IRC-confirmed', 'response >PR until the first date of IRC-confirmed PD or death due to any cause,', 'whichever occurs first', 'ORR1 (ORR for SVdX patients only)', 'Confidential', 'Page 45', 'Version 4.0']\n\n###\n\n", "completion": "END"}